Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu (R)

摘要

Influenza viruses cause annual winter epidemics globally and influenza vaccination is most effective way to prevent the disease or severe outcomes from the illness, especially in developing countries. However, the majority of the world's total production capacity of influenza vaccine is concentrated in several large multinational manufacturers. A safe and effective preventive vaccine for the developing countries is urgent. Anflu (R), a Chinese domestic preservative-free, split-virus trivalent influenza vaccine (TIV), was introduced by Sinovac Biotech Ltd. in 2006. Until now, 20.6 million doses worldwide of Anflu (R) were sold. Since 2003, 13 company-sponsored clinical studies investigating the immunogenicity and safety of Anflu (R) have been completed, in which 6642 subjects participated and were vaccinated by Anflu (R). Anflu (R) was generally well tolerated in all age groups, and highly immunogenic in healthy adults and elderly and exceeded the licensure criteria in Europe. This review presents and discusses the experience with Anflu (R) during the past decade.